



## Dr. Denis Claude Roy

Dr. Denis Claude Roy is a hematologist and clinical researcher. After a research fellowship at Harvard University's Dana-Farber Cancer Institute, he began his practice at Maisonneuve-Rosemont Hospital in Montreal in 1990. There, he set up the Clinical Cell Therapy Laboratory as well as his Translational Cell Therapy Research Laboratory, where he develops immunotherapeutic and photodynamic approaches to eliminate cancer cells and prevent graft-versus-host disease, which he also evaluates in Phase I, II and III clinical trials.

In 2012, Dr. Roy was awarded the construction of Canada's largest cell therapy production center (CETC), with 14 clean rooms. To this day, the CETC remains one of the largest centers in Canada. For 14 years, Dr. Roy was Scientific Director of the Maisonneuve-Rosemont Hospital Research Center. In 2008, he co-founded the ThéCell cell, tissue and gene therapy network, which he will co-direct until 2023. In 2014, Dr. Roy also created CellCAN, a pan-Canadian network for regenerative medicine and cell therapy aimed at mobilizing knowledge and best practices. In 2016, he co-founded and has since been Scientific Director of C3i Centre, offering development and contract manufacturing services in cell and gene therapy.

In recognition, among others, of Dr. Roy's expertise, the Quebec government is granting HMR the designation of Hematology-Oncology and Cell Therapy University Institute (IHOT) in 2019, and his efforts are leading to the current construction of a gene therapy (viral vector) manufacturing unit, the first of its kind in Canada's public sector.

Dr. Denis Claude Roy has 140 research publications and 174 abstracts in peer-reviewed journals, and is an external referee for over 30 journals. He has secured over \$100 million in funding as principal or co-principal investigator, including \$50 million for infrastructure and over \$22 million to set up cancer and cell therapy organizations.

